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Microtubule-associated protein tau contains a consensus motif for protein kinase B/Akt (Akt), which plays an essential role in anti-
apoptotic signaling. The motif encompasses the AT100 double phospho-epitope (Thr212/Ser214), a specific marker for Alzheimer’s disease
(AD) and other neurodegenerations, raising the possibility that it could be generated by Akt. We studied Akt-dependent phosphorylation of
tau protein in vitro. We found that Akt phosphorylated both Thr212 and Ser214 in the longest and shortest tau isoforms as determined using
phospho site-specific antibodies against tau. Akt did not phosphorylate other tau epitopes, including Tau-1, AT8, AT180, 12E8 and PHF-1.
The Akt-phosphorylated tau retained its initial electrophoretic mobility. Immunoprecipitation studies with phospho-specific Thr212 and
Ser214 antibodies revealed that only one of the two sites is phosphorylated per single tau molecule, resulting in tau immunonegative for
AT100. Mixed kinase studies showed that prior Ser214 phosphorylation by Akt blocked protein kinase A but not GSK3h activity. On the
other hand, GSK3h selectively blocked Ser214 phosphorylation, which was prevented by lithium. The results suggest that Akt may be
involved in AD-specific phosphorylation of tau at the AT100 epitope in conjunction with other kinases. Our data suggest that
phosphorylation of tau by Akt may play specific role(s) in Akt-mediated anti-apoptotic signaling, particularly relevant to AD and other
neurodegenerations.
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Tau is a microtubule-associated protein that plays a
regulatory role in microtubule assembly and stability in
neuronal and glial cells. Normal adult brain contains six
tau isoforms, which are derived from alternative splicing.
Expression of tau isoforms is developmentally regulated and
only a single tau isoform is found in fetal human brain [1].
Interactions of tau with microtubules are regulated by the
length of the microtubule-binding domain [2] and by
phosphorylation [3]. Specific roles of different phosphory-
lation sites in tau have been demonstrated in the develop-
ment of cell processes [4], axonal transport [5] and Fyn-
mediated signal transduction [6].
Deposits of tau, designated as paired helical filaments
(PHFs), characterize a number of late onset neurodegener-0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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other age-related dementias with tauopathy [7,8]. PHFs are
composed of highly phosphorylated species of tau but the
molecular mechanism leading to hyperphosphorylation and
deposition of tau in late onset dementias remains unclear.
Hyperphosphorylated tau in PHFs contains a unique double-
site phospho-epitope AT100 (Thr212/Ser214). This epitope
merits particular attention since it is specific to PHFs and,
unlike other phospho-epitopes associated with PHFs, is
absent in biopsy-derived normal tau [9]. Studies in vitro
have shown that the AT100 epitope could be generated in a
sequential phosphorylation first by glycogen synthase ki-
nase-3h (GSK3h) at Thr212, then by protein kinase A
(PKA) at Ser214 [10].
Studies have demonstrated that tau phosphorylation sites
containing Ser–Pro or Thr–Pro motifs have only a moder-
ate effect on the dynamic instability of microtubules as
compared with non-proline sites, e.g., Ser214 and Ser262
[11]. Phosphorylation at Ser214 is of particular importance
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reducing tau’s affinity for microtubules by a factor of 10
[12]. Moreover, unlike Ser–Pro or Thr–Pro motifs phos-
phorylated by GSK3h and other kinases, phosphorylation at
Ser214 has been reported to have a protective effect against
tau assembly into PHFs [13]. Effects of Thr212 on micro-
tubule binding and PHF-like aggregation have not been
examined mostly due to difficulties in generating tau phos-
phorylated at a single site.
Akt/protein kinase B (Akt) has not been considered as a
potential kinase in generating AT100 epitope or in tau
phosphorylation studies. However, the AT100 epitope
encompasses a consensus motif for Akt [14] strongly
suggesting that phosphorylation of tau in this region could
result from activation of a signaling pathway involving Akt
[15]. Akt is a 57 kDa Ser/Thr kinase and a downstream
effector of the PI3K/Akt anti-apoptotic signaling cascade
[16–18]. It is widely expressed, with all tissues containing
at least one form of Akt and highest levels in brain, thymus,
heart, and lung [16,19]. The activation of Akt is achieved by
phosphorylation at Thr308 and Ser473 by a mechanism
either dependent or independent of PI3K activation by
growth factors. Downstream targets of Akt include tran-
scription factors, anti-apoptotic gene expression and regu-
lation of the cell cycle. Akt effectively inhibits GSK3a/h by
phosphorylating Ser21/9 [20]. Furthermore, Akt redistrib-
utes hexokinase activity to the mitochondria, couples gly-
colysis to oxidative phosphorylation and blocks release of
cytochrome c to inhibit apoptosis [21,22].
In the present studies, using site-specific antibodies, we
demonstrate that Akt is able to phosphorylate tau in at least
two sites, Thr212 and Ser214, but not simultaneously. Akt-
phosphorylated tau can be separated into two pools each
containing only a single phospho-site, either Thr212 or
Ser214. The results suggest that activation of Akt may
partially contribute to specific tau phosphorylation at the
AT100 epitope characteristic of PHFs.2. Materials and methods
2.1. Materials
Alkaline phosphatase (E. coli, type III), GSK3h (rabbit
recombinant), PKA (bovine heart, P5511), protease inhib-
itors and other general chemicals were purchased from
Sigma, St. Louis, MO. H-7 was purchased from Seikagaku,
Tokio, Japan and KT5720 from Calbiochem, La Jolla, CA.
Fat-free milk was from Carnation. Nitrocellulose mem-
branes, secondary antibodies conjugated to horseradish
peroxidase and protein assay kit were from BioRad, Redd-
ing, CA. Enhanced chemiluminescence (ECL) kit was
purchased from Amersham, Arlington Heights, IL. Akt
kinase was from Panvera Corporation, Madison, WI. Protein
G Sepharose was purchased from Pharmacia, Uppsala,
Sweden. GSK3a/h fusion protein and Akt kinase assay kitwere obtained from Cell Signaling Technology, Inc., Bev-
erly, MA (New England Biolabs).
2.2. Recombinant tau
Recombinant human tau was expressed in E. coli BL21
(DE3 cells) using an expression plasmid pRK172 containing
a tau cDNA (clone htau40). Clone htau40 encodes the
longest tau isoform of 441 amino acid residues and was a
generous gift from Michel Goedert [1]. The induction,
expression and the isolation of recombinant tau was per-
formed as previously described [23,24]. Protein concentra-
tion was determined using a protein assay based on
Coomassie brilliant blue G-250 binding.
2.3. Tau preparations
Tau fraction was isolated from fetal human brain (19–21
gestational age) as previously described using perchloric
acid extraction [25] and used without further treatments
(Ftau). Some Ftau preparations were subjected to alkaline
phosphatase treatment for 24 h to dephosphorylate endog-
enous sites as described [25]. After dephosphorylation,
samples were adjusted to 0.3 M NaCl and 2% h-mercap-
toethanol, boiled for 10 min and centrifuged at 15,000 g
for 15 min. The supernatant was dialysed in 50 mM Tris/
HCl, pH 7.4 and the obtained fraction designated FtauAP.
2.4. Polyacrylamide gel electrophoresis and Western
blotting
Proteins were separated by electrophoresis using SDS-
polyacrylamide gels containing 10% polyacrylamide. Sepa-
rated proteins were electrotransferred onto nitrocellulose
membranes. Immunoblotting was performed using 5% fat-
free milk in Tris-buffered saline (TBS) to block nonspecific
binding sites and to dilute the primary and secondary anti-
bodies. Specific protein signals were detected by ECL.
2.5. Antibodies
Monoclonal antibodies raised against phospho-tau in-
cluded AT8 (Ser202/Thr205), AT100 (Thr212/Ser214) and
AT180 (Thr231) from Innogenetics, Belgium. Other anti-
bodies against phospho-tau included the rabbit anti-pThr212
(Calbiochem), the rabbit anti-pSer214 (Abcam), the mono-
clonal antibody 12E8 (Ser262/356, Athena Neuroscience),
and the monoclonal antibody PHF-1 (Ser396/404, Albert
Einstein Coll. Med.). The monoclonal antibody raised
against non-phosphorylated tau was Tau 46 (the C-terminal
residues 428–441; Zymed). Other antibodies included the
rabbit anti-phospho-GSK3a/h (Ser21/9), the monoclonal
antibody, 4E2, raised against phospho-Akt (Ser473) and
the rabbit antibody raised against phospho-(Ser/Thr) Akt
substrate (PAS) from Cell Signaling. The rabbit anti-phos-
pho-Akt1/PKBa (Ser473) was obtained from Upstate and
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2.6. Kinase assays
Tau and other substrates were incubated with respective
kinases in a kinase buffer mixture containing 25 mM Tris/
HCl, pH 7.5, 5 mM h-glycerophosphate, 2 mM dithio-
threitol, 0.1 mM sodium vanadate, 10 mM MgCl2, 0.1 mg/
ml heparin and either 3 mM ATP (Akt and GSK3h) or 3
mM bdcAMP (PKA). Tau protein was added at 2–5 Ag and
GSK3a/h fusion protein at 5–10 Ag per 50 Al final
volume. Akt kinase was an active form of human recom-
binant Akt1 obtained as >90% purified preparations [26]
and was used at 0.54 Ag/50 Al (equivalent to the activity of
0.25 nmol/min at 30jC with Crosstide peptide as sub-
strate). PKA was used at 10 Ag/50 Al, and GSK3h at 1 unit/
50 Al. Except for immunoprecipitation studies, the enzy-
matic reactions were terminated by adding SDS-sample
buffer. In some experiments, specific kinase inhibitors were
used, lithium chloride (50 mM) for GSK3a/h, KT5720 (3
AM) for PKA, staurosporine (10 nM) for PKC and other
kinases (e.g., cdc2), and H-7 (30 AM) for both PKA and
PKC [27–29].
2.7. Immunoprecipitation
Five-microliter samples from the kinase reaction contain-
ing phospho-tau were diluted 10-fold with the lysis buffer
(20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-Fig. 1. A diagram illustrating the region of tau molecule encompassing the AT100
for phosphorylation by Akt based on Alessi et al. [14]. The underlined tau sequen
requirements for Akt-dependent phosphorylation, with Arg residues at positions
residues at positions n-1 and n-3. GSK3h and PKA are protein kinases previouslphate, 1 mM h-glycerolphosphate, 1 mM Na3V04, 1 Ag/ml
leupeptin and 0.1 mM PMSF) and incubated with the rabbit
anti-tau antibodies (anti-pThr212 and anti-pSer214) for 3–5
h at 4jC. After the incubation, the mixture was combined
with 40–20 Al pellet of protein G Sepharose prewashed
twice in the lysis buffer. Samples were rocked gently for 2
h at 4jC and then separated into the supernatants and pellets
(immune complexes). The supernatants were used either for
immunoblotting or to perform the second kinase reaction.
Pellets of the immune complexes were washed three times
with 250 Al lysis buffer and then suspended in the SDS-
sample buffer.3. Results
3.1. Tau protein contains the Akt kinase consensus motif
The Akt consensus motif has been described in a number
of proteins considered as substrates for Akt [14]. The
examination of the primary sequence of tau reveals the
presence of a single Akt motif, which coincides with the
AT100 epitope (Fig. 1) [30]. Among Akt consensus motif,
there is a stringent requirement for Arg residues at positions
n-3 and n-5, where n is the site of phosphorylation. In tau,
only Ser214 conforms to this requirement. It was uncertain
whether Thr212, which has Arg residues at positions n-1
and n-3, and is also a part of the AT100 epitope, could be
phosphorylated by Akt. In the present studies, we sought to
determine directly whether one or both amino acid residues
could indeed be phosphorylated by Akt in vitro.epitope (double-phospho site Thr212/Ser214) and the consensus sequence
ce comprises the consensus motif with Ser214 conforming to the stringent
n-3 and n-5. Thr212 only partially conforms to this requirement with Arg
y shown to phosphorylate Thr212 and Ser214, respectively [10,32,33].
et Bi3.2. Characterization of tau substrates
To determine the dependence of Akt activity on the size
of the tau molecule, we selected the longest (rtau) and the
shortest (Ftau and FtauAP) human tau isoforms as the
potential Akt substrates. Rtau (441 amino acid residues)
contains the N-terminal inserts and four repeats in the
microtubule binding domain. The shortest tau isoform
(352 amino acid residues) contains only three repeats in
the microtubule binding domain and lacks the N-terminal
inserts. Furthermore, to determine whether Akt activity
depends on prior phosphorylation state of tau, fetal tau
preparations either contained endogenous phosphorylation
sites (Ftau) or were subjected to prior dephosphorylation
(FtauAP). Characterization of tau substrates by SDS-PAGE
and immunoblotting demonstrated their purity, well-estab-
lished migration pattern, and immunoreactivity with phos-
pho-dependent and -independent tau antibodies (Fig. 2).
Rtau but not Ftau or FtauAP preparations contained degrad-
ed tau fragments. These fragments were Tau 46-negative
and most likely devoid of the C-terminal end. The prepara-
tions differed in the phosphorylation status of tau. Ftau
immunoreacted with more phospho-dependent tau antibod-
ies than the other two preparations (Figs. 2C and 3D). This
was consistent with Ftau having a high content of up to
seven phosphate residues per molecule and other prepara-
tions either having no or very low phosphate content
[25,31]. A low phosphorylation status of FtauAP was
additionally confirmed by its faster electrophoretic mobility
than that of Ftau (48 vs. 55 kDa). Neither of the tau
preparations were immunoreactive for pThr212 (Fig. 2D)
but all were immunoreactive for pSer214 (Fig. 2E). Of the
three, Ftau displayed the most intense pSer214 immunore-
activity, whereas rtau and FtauAP were only weakly immu-
noreactive (Fig. 2D,E). The weak binding could be either
due to a low phosphorylation level of pSer214 in these
preparations or to cross-reactivity of non-phosphorylated
Ser214 and/or surrounding amino acid residues.
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immunoblotted with tau antibodies for total tau (Tau 46) and phosphorylated ta
human tau (rtau); lane 2, fetal tau isolated from human brain (Ftau); and lane 3, f
FtauAP in molecular size (441 vs. 352 amino acid residues). FtauAP has a faster
anti-pSer214 but not other phospho-tau antibodies cross-react with non-phosphor
similar cross-reactivity or a low phosphorylation level at this site. Protein loading3.3. Akt phosphorylates tau at Thr212 and Ser214
We characterized the activity of purified >90% prepara-
tions of full-length human Akt (Fig. 3A) with its GSK3a/h
substrate. We used the f 30 kDa GSK3a/h fusion protein
containing Ser21/9, the site specific for Akt phosphoryla-
tion, and found that incubation with Akt for 1 and 5
h increased its phospho-Ser21/9 immunoreactivity in a
time-dependent manner (Fig. 3B).
Incubation of tau protein substrates (rtau, Ftau, FtauAP)
with the same preparation of Akt elevated the immunore-
activity of tau with anti-pThr212 and anti-pSer214 anti-
bodies, regardless of whether tau contained endogenous
phosphorylation sites or varied in its molecular size (Fig.
3C). The increases appeared to reach a plateau by approx-
imately 1 h of incubation under our experimental condi-
tions. Other phospho-epitopes probed with a panel of
antibodies against tau (Tau-1, AT8, 12E8, AT180, PHF-1,
AT100) were unaltered by incubation with Akt except for
Ftau which showed decreases in the PHF-1 immunoreactiv-
ity (Fig. 3D). It is still possible that Akt could phosphorylate
other sites, which were not tested. The Akt-dependent
phosphorylation had no apparent effect on the electropho-
retic mobility of tau.
3.4. Comparisons of Akt with GSK3b and PKA
In order to confirm that Akt-dependent phosphorylation
of tau was not due to potentially contaminating protein
kinases PKA or PKC we used specific and general inhibitors
(KT5720, H-7 and staurosporine). As shown in Fig. 4, the
inhibitors were without a significant effect on Akt-depen-
dent phosphorylation of tau at the two phospho-epitopes.
We concluded that Thr212 and Ser214 were unlikely to be
phosphorylated by PKA or PKC potentially contaminating
preparations of Akt. We also concluded that the potential
role of tau phosphorylation by GSK3h is minimal since Akt
is a potent inhibitor of this protein kinase. Moreover, we did
ophysica Acta 1639 (2003) 159–168el electrophoresis and either stained with (A) Coomassie blue, or (B–E)
u epitopes (PHF-1, anti-pThr212, and anti-pSer214). Lane 1, recombinant
etal tau treated with alkaline phosphatase (FtauAP). Rtau differs from Ftau/
mobility than Ftau due to dephosphorylation of endogenous sites. Note that
ylated Ser214 in rtau. Weak pSer214 staining of FtauAP may be due to a
was 0.25–0.5 Ag for Coomassie blue and 0.1 Ag for immunoblots.
Fig. 3. Akt kinase activity with various substrates. (A) Preparation of active
Akt1 (human recombinant, r-pAkt) stained with Coomassie blue (CB) or
immunoblotted with the antibody against pSer473-Akt. Loading was 0.5
and 0.05 Ag, respectively. (B) GSK3a/h fusion protein incubated with Akt
for 0–5 h and immunoblotted for phospho-Ser21/9. (C) Three tau
preparations incubated with Akt for 0–5 h and immunoblotted with anti-
pThr212, anti-pSer214 and Tau 46 (total tau) antibodies as indicated. Note
the time-dependent elevation of phospho-tau immunoreactivity in all
preparations. In Ftau, a range of Tau 46-reactive tau species was
significantly wider at 1–5 h than 0 h and the immunoreactivity appeared
stronger. This could be due to endogenous protease or phosphatase
activities generating faster migrating tau species. (D) Samples in C
immunoblotted with a panel of phospho-dependent tau antibodies and Tau-
1, whose binding is blocked by phosphorylation. No significant increases
were noted over the period of 0–5 h incubation, suggesting that Akt was
inactive at these sites. In Ftau, decreases in the PHF-1 immunoreactivity
during the incubation suggest the presence of phosphatase activities in this
preparation.
Fig. 4. Akt and protein kinase inhibitors. FtauAP was incubated with Akt
for 1 h in the absence (None) or presence of inhibitors KT5720 (3 AM),
staurosporine (10 nM), and H-7 (30 AM) as indicated. The immuno-
reactivity with (A) anti-pThr212 and (B) anti-pSer214 showed no
significant effect of these inhibitors on tau phosphorylation.
H. Ksiezak-Reding et al. / Biochimica et Biophysica Acta 1639 (2003) 159–168 163not detect any pGSK3a/h in Akt preparations by immuno-
blotting (Fig. 3B, 0 h).
GSK3h and PKA have previously been shown to phos-
phorylate Thr212 and Ser214 of tau, respectively
[10,32,33]. We selected these two enzymes to compare
their site specificity with that of Akt. The results obtained
using FtauAP showed that both Akt and GSK3h phosphor-
ylated Thr212 in a similar time-dependent manner between
0 and 60 min incubation (Fig. 5A,B). In contrast to Akt,
however, the incubation with GSK3h resulted in an upward
mobility shift of FtauAP from 48 (arrows) to 55 kDa,
reaching that of Ftau. The results indicate that besides
Thr212, other epitopes of tau were also phosphorylated
by GSK3h as shown earlier [34,35]. This conclusion was
confirmed by finding elevated immunoreactivity with PHF-
1 in parallel samples (Fig. 5B). Unlike Akt, GSK3h showed
negligible phosphorylation of Ser214. Similar studies with
PKA revealed phosphorylation of tau at Ser214 but not
Thr212 (Fig. 5C), consistent with the previous evidence
[33]. PKA caused the upward mobility shift of a fraction of
tau protein indicating the involvement of other tau epitopes
besides Ser214, as reported earlier [12,32]. The shift in
mobility with PKA was less prominent than with GSK3h.
These comparisons underline a unique specificity of Akt to
phosphorylate both Thr212 and Ser214 of tau. Our results
also indicate that anti-pThr212 and anti-pSer214 antibodies
bind their specific tau epitopes in a selective manner,
without apparent overlap.
3.5. Akt phosphorylates Thr212 and Ser214 separately
It was interesting to note that Akt-dependent phosphor-
ylation of tau at both Thr212 and Ser214 was ineffective
in inducing immunoreactivity with AT100 (see Fig. 3D,
second row). This was not due to a low concentration of the
antibody used since parallel samples of positive control
(PHF-tau fraction isolated from AD brain) were found
highly immunoreactive (not shown). The negative results
with AT100 could be explained if Thr212 and Ser214 were
phosphorylated in two separate rather than in a single tau
molecules. In order to test this idea, we immunoprecipitated
Fig. 5. Comparisons of site-specificity of Akt, GSK3h and PKA. FtauAP was incubated with respective kinases for 0–60 min and immunoblotted with tau
antibodies as indicated. (A) Akt, (B) GSK3h, and (C) PKA. Note a differential phosphorylation of Thr212 and Ser214 by GSK3h and PKA but not Akt. Except
for Akt, other kinases resulted in upward mobility shift of tau from 43 kDa to 55 kDa (GSK3h) or 52 kDa (PKA). In C, in order to demonstrate PKA-induced
shift in the mobility of tau, blots were developed with Tau 1 (FtauAP-positive) instead of PHF-1 (FtauAP-negative). Arrows indicate the initial FtauAP mobility
at 48 kDa.
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pSer214 antibodies. The resulting immuno-pellets and
-supernatants were tested for the presence of tau protein
with specific phospho-epitopes. The results showed that tau
fraction could indeed be separated into two distinct pools,Fig. 6. Immunoprecipitation of distinct species of phospho-tau. FtauAP incubated
pSer214 antibodies. Immunopellets and supernatants demonstrate distinct pools o
pattern of immunoreactivity between pellet and supernatant fractions in A and B.
detected only in pellets. (C) The total and supernatant fractions from A and B imm
Note that both pools of tau bind the PAS antibody.each containing tau with a single phospho-epitope, either
pThr212-tau or pSer214-tau. For example, immunoprecipi-
tation with anti-pThr212 resulted in the immunoprecipitate
positive for pThr212 but not pSer214 (Fig. 6A, pellet).
Moreover, tau remaining in the supernatant was immunore-with Akt for 1 h and immunoprecipitated with (A) anti-pThr212 or (B) anti-
f tau enriched either for pThr212- or pSer214-tau. Note the complementary
Black arrows mark the position of immunoglobulin heavy chain (H. chain)
unoblotted with an antibody against a generic phospho-Akt substrate (PAS).
Fig. 7. Mixed kinases. (A) FtauAP incubated with Akt for 1 h and
immunoprecipitated to obtain supernatants enriched in pThr212-tau (left
panel) or pSer214-tau (right panel). The supernatants incubated for an
additional 30 min with none (lanes 1 and 3), GSK3h (lane 2) or PKA (lane
4). Note that GSK3h but not PKA elevated tau immunoreactivity and
caused a shift in the mobility of tau. (B) FtauAP incubated with GSK3h for
30 min and then supplemented with either no (lanes 1 and 3) or Akt alone
(no lithium) for another 30-min incubation (lanes 2 and 4). Note that Akt
was active with Thr212 but inactive with Ser214. (C) FtauAP incubated
with GSK3h for 30 min and then supplemented with 50 mM lithium (lanes
1 and 3) or Akt plus 50 mM lithium for another 30-min incubation (lanes 2
and 4). Note that Akt was active with both Thr212 and Ser214 in the
presence of lithium. (D) FtauAP incubated with GSK3h for 30 min and
then supplemented with PKA alone (lane 1) or PKA plus 50 mM lithium
(lane 2) for another 30-min incubation. Note the robust PKA activity under
both conditions.
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supernatant). A complementary pattern of immunoreactivity
was obtained using an immunoprecipitation assay with anti-
pSer214 (Fig. 6B). These results indicate that Akt phos-
phorylates two sites of tau Thr212 and Ser214, but each site
is on a different tau molecule. Therefore, only one site, either
Thr212 or Ser214 can be phosphorylated in a single tau
molecule.
It was unclear which of the two sites was the preferred
phosphorylation site for Akt. To determine the ratio between
two pools of phospho-tau, we quantified the total tau
immunoreactivity (Tau 46) in the corresponding immuno-
precipitates and supernatants. The obtained ratio between
the pThr212- and pSer214-enriched pools of tau was 4.3:1
(n = 8), indicating that Thr212 was the preferred phosphor-
ylation site for Akt.
3.6. Akt-phosphorylated tau binds PAS antibody
To further confirm that both sites of tau Thr212 and
Ser212 can be recognized as potential substrates for Akt,
we used the antibody PAS. This antibody has been raised
against a generic phospho-Akt substrate peptide and shown
to preferentially bind proteins containing phospho-Thr/Ser
preceded by Lys/Arg at positions  5 and  3. The
pThr212- and pSer214-enriched pools of tau were obtained
by immunoprecipitation and collection of supernatants (see
also Fig. 6A,B, IP supernatants) and analyzed by Western
blotting with PAS. The results showed that both pools of
tau bound PAS and therefore could be recognized as
generic Akt substrates (Fig. 6C). The PAS binding occurred
despite the fact that only Ser214 was preceded by Arg
residues required at positions  5 and  3, whereas
Thr212 was preceded by Arg at positions  1 and  3.
This finding additionally supports our conclusion based on
direct Akt phosphorylation studies that both sites in the
AT100 epitope are recognized by Akt and may serve as
phosphate acceptors.
3.7. Akt blocks PKA- but not GSK3b-dependent phosphor-
ylation of tau
Our present studies (Fig. 5) and previous reports indicate
that both GSK3h and PKA phosphorylate multiple sites in
tau and cause a significant upward shift in the electropho-
retic mobility of this protein. Since Akt was able to
phosphorylate only selected sites recognized by GSK3h
and PKA, we asked whether prior Akt activity could block
tau from further interactions with these kinases and prevent
changes in tau mobility. To address this question, we first
incubated Akt with FtauAP for 1 h to obtain a mixture of
pThr212-tau and pSer214-tau and then separated individual
species of phospho-tau by immunoprecipitation as described
in Fig. 6. The supernatant enriched in pThr212-tau was
incubated with GSK3h and this treatment caused the up-
ward mobility shift of tau (Fig. 7A, lane 2). The supernatant
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mobility shift of tau was not detected (Fig. 7A, lane 4). The
results indicated that prior phosphorylation of tau by Akt
had no apparent inhibitory effect on further interactions of
tau with GSK3h. Prior phosphorylation by Akt, however,
could block further interactions of tau with PKA, as judged
by tau mobility.
3.8. GSK3b blocks Akt- but not PKA-dependent phosphor-
ylation of tau
Next, we asked whether prior phosphorylation by GSK3h
precluded interactions of tau with Akt. In these experiments,
GSK3h was incubated with FtauAP for 30 min, then the
reaction mixture was supplemented either with buffer or Akt
and incubated for another 30 min. Immunoblotting analysis
of the final reaction products showed that GSK3h alone
phosphorylated Thr212 but very little of Ser214 (Fig. 7B,
lanes 1, 3), as expected. Incubation with both GSK3h and
Akt improved phosphorylation of Thr212 but largely
inhibited phosphorylation of Ser214 by Akt (Fig. 7B, lanes
2, 4). These results suggest that GSK3h selectively pre-
vented Akt from phosphorylating Ser214 but not Thr212.
We asked whether inhibition of GSK3h by lithium could
enable Akt to phosphorylate Ser214. These experiments
were performed as above, except that the second 30-min
incubation was carried out either in the presence of 50 mM
lithium (Fig. 7C, lanes 1, 3) or Akt and 50 mM lithium (Fig.
7C, lanes 2, 4). The immunoblotting analysis showed that
the presence of lithium had little stimulatory effect on
phosphorylation of Thr212 by Akt (Fig. 7C, lane 2) but
dramatically improved phosphorylation of Ser214 (Fig. 7C,
lane 4).
Parallel studies with GSK3h and PKA determined that
prior incubation of tau with GSK3h had no inhibitory effect
on PKA activity with tau and phosphorylation of Ser214,
regardless of whether lithium was present or not (Fig. 7D).4. Discussion
The results of the present studies demonstrate that Akt
incorporates phosphate groups in two sites of tau protein in
vitro. The phosphorylation of tau is independent of the size
of the tau molecule as determined using the longest and the
shortest tau isoforms. It is also independent of prior (en-
dogenous) phosphorylation of tau. One site phosphorylated
by Akt is Ser214, which fulfills the stringent requirement for
Arg residues at positions n-3 and n-5. In addition, Akt also
phosphorylates Thr212, which conforms less rigorously to
this requirement, with Arg residues at positions n-1 and n-3.
Moreover, Thr212 is phosphorylated 4.3-times more effi-
ciently than Ser214 and binds equally well to antibody
raised against a generic phospho-substrate of Akt. Further,
Akt-dependent phosphorylation of tau has an unusual fea-
ture in that only a single site, either Thr212 or Ser214, canbe phosphorylated per tau molecule. This is not due to
potential contaminating kinases since PKA, PKC and
GSK3h inhibitors were ineffective in blocking Akt kinase
activity. The results of the present studies strongly suggest
that phosphorylation of tau by Akt has a specific physio-
logical role(s).
The putative role of Akt-dependent tau phosphorylation
could be related to tau function as a microtubule-associated
protein. The phosphorylation of Ser214 or pseudophosphor-
ylation by conversion of Ser214 to Asp have been demon-
strated to potently inhibit tau binding to microtubules and
suppress tau ability to promote microtubule assembly [12]
or microtubule nucleation [36]. Moreover, the phosphory-
lation of Ser214 has been detected in metaphase but not in
interphase of tau-transfected CHO cells, suggesting its
potential role in cell cycle activities such as detachment of
tau from mitotic microtubules.
The important role of Ser214 is underlined by the fact
that at least two kinases, including Akt and PKA, are
responsible for the site-specific phosphorylation. For PKA
activity, Ser214 appears to be a primary target. Our obser-
vations extend this idea by showing that prior phosphory-
lation of Ser214 by Akt disrupts or inhibits PKA activity
towards tau (Fig. 7A). This is particularly evident in
comparisons to GSK3h, which has no apparent inhibitory
effect on PKA activity (Fig. 7D). Our results suggest that
there may be a relationship (competition) between Akt and
PKA in regulating tau interactions with microtubules and
that Ser214 controls these interactions. Alternatively, phos-
phorylation of Ser214 may be a part of the redundant
mechanism controlling microtubule binding. This mecha-
nism appears to be activated in dividing cells since a
significant upregulation of pSer214-tau has been demon-
strated in mitotic cells but not in interphase [12]. Similar
mechanism controlling microtubule binding via pSer214
and Akt may play a role in regulation of synaptic strength
[37]. It is unclear whether Ser214 plays other roles, e.g., in
cell apoptosis.
Phosphorylation of Ser214 has been implied to play a
protective role in the formation of abnormal tau aggregates
in neurodegenerative disorders [13]. The fact that Akt may
be involved in this protection suggests that tau is a candidate
factor in PI3K/Akt anti-apoptotic signaling. It also suggests
that phosphorylation of tau may play a protective role in cell
survival. Such a role has been postulated with regard to
cultured neurons [38] and neurofibrillary tangle/PHF for-
mation in AD brain [39,40]. It is conceivable that phos-
phorylation of Ser214 may facilitate microtubule-based
trafficking of organelles by causing detachment of tau from
microtubules [5]. This could be necessary for neuronal
survival. On the other hand, other studies applying a
pseudohyperphosphorylation model of AD in cultured cells
indicate that phosphorylation of tau may impart toxic gain
of function and contribute to neuronal death [41]. Further
studies need to resolve the important issue of the role of tau
phosphorylation in neurodegeneration.
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strated in AD brain [42]. The expression followed the
pattern of localization in neurons consistent with the early
events in the pathogenesis of neurofibrillary changes. Such
studies provide independent evidence supporting the view
that Akt could be involved in tau metabolism in vivo and
play a protective role in cellular responses in neurodegen-
eration [43].
In comparison to Ser214, Thr212 appears to have a less
significant role in regulating binding to microtubules. In this
respect, Thr212 is similar to other Thr–Pro and Ser–Pro
sites, targets of proline-directed kinases such as GSK3h [4].
It is conceivable that phosphorylation of Thr212 plays other
roles, e.g., modulating phosphorylation of Ser214. Further
studies need to determine the role of the Akt-dependent
phosphorylation of Thr212.
It was interesting to note that GSK3h effectively blocked
interactions of Akt with Ser214, the site not phosphorylated
by GSK3h. One explanation is that GSK3h activity could
change the conformation of tau and block access to Ser214.
This suggestion is less likely, however, since Akt is active
towards GSK3h-phosphorylated tau in the presence of
lithium (Fig. 7C) and towards endogenously phosphorylated
tau as well (Fig. 5A). Alternatively, this inhibition could be
due to the presence of GSK3h itself since 50 mM lithium
alone was able to reverse the inhibition. For example,
GSK3h could sequester tau as demonstrated for non-phos-
phorylated tau [44] or it could sequester Akt. It is conceiv-
able that lithium binding by GSK3h may release the
sequestered proteins and reverse the inhibition. Which of
these interpretations is correct will require further studies.
Our results indicate that Akt introduces only one phos-
pho-residue per tau molecule in vitro and thus may generate
one part of the double phospho-epitope AT100, either
pThr212 or pSer214. Is unclear which other kinase(s) could
contribute to the complementary phosphorylation. Our
results suggest that the GSK3h-Akt combination may be
effective (in the presence of lithium) as well as the Akt–
PKA combination under specific conditions. Further exami-
nations need to consider also other kinases not tested in the
present studies, e.g., cdk5 or cdc2.
In summary, the ability of Akt to phosphorylate tau not
only suggests that tau is a candidate factor in the PI3K/Akt
signaling pathway but also supports the recent view that
changes in phosphorylation of tau represent an integral part
of the normal signal-processing machinery [45,46].Acknowledgements
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